[vc_row top_margin=”none” el_position=”first”] [vc_column top_margin=”none”] [mc_carousel id=”carousel” carousel_images=”2773,2772,2771,2770″ features_images_loop=”1″ lightbox_icon_color=”blue_light” autoplay=”0″ pause_on_hover=”1″ scroll=”1″ effect=”scroll” easing=”swing” duration=”500″ top_margin=”page_margin_top_section” el_position=”first last”] [/vc_column] [/vc_row] [vc_row top_margin=”none” el_position=”last”] [vc_column top_margin=”none”] [vc_column_text el_position=”first last”]

Kinase Inhibitor Favorable for Drug-Resistant Thyroid Cancer
February, 2018
https://specialty.phamacytimes.com/news/kinase-inhibitor-favorable-for-drug-resistant-thyroid-cancer

Cabozantinib shows promise as first line treatment for differentiated thyroid cancer
February 13, 2018
https://www.sciencedaily.com/releases/2018/02/180213123249.htm

I am text block. Click edit button to change this text.Molecular Testing Panel Increases Likelihood of Performing Correct Surgery for Thyroid Cancer Patients
News Medical
July31, 2014
http://www.news-medical.net/news/20140726/Molecular-testing-panel-increases-likelihood-of-performing-correct-surgery-for-thyroid-cancer-patients.aspx

EMA Approves Eisai’s Lenvatinib for Accelerated Assessment in Radioiodine-Refractory Differentiated Thyroid Cancer
MarketWatch
July 31, 2014
http://www.marketwatch.com/story/ema-approves-eisais-lenvatinib-for-accelerated-assessment-in-radioiodine-refractory-differentiated-thyroid-cancer-2014-07-30

CEL-SCI expands late-stage head and neck trial
Nasdaq
July, 2014
http://www.nasdaq.com/article/celsci-expands-latestage-head-and-neck-cancer-trial-into-sri-lanka-20140717-00479

Nexavar Approval Widens
ThyCa: Thyroid Cancer
July, 2014
http://www.thyca.org/news/newsnotes0614#nexavar

[/vc_column_text] [/vc_column] [/vc_row]